Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.

Détails

ID Serval
serval:BIB_C865C2384022
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
Périodique
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Auteur⸱e⸱s
Viscoli C., Cometta A., Kern W.V., Bock R., Paesmans M., Crokaert F., Glauser M.P., Calandra T., Treatment of Cancer
Collaborateur⸱rice⸱s
International Antimicrobial Therapy Group of the European Organization for Research
Contributeur⸱rice⸱s
Treatment of Cancer
ISSN
1198-743X (Print)
ISSN-L
1198-743X
Statut éditorial
Publié
Date de publication
03/2006
Peer-reviewed
Oui
Volume
12
Numéro
3
Pages
212-216
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
Publication Status: ppublish
Résumé
Combination therapy with a beta-lactam plus an aminoglycoside has been the standard approach for treating febrile neutropenia for many years. More recently, beta-lactam monotherapy has also been shown to be a reliable and safe approach. In the present study, 763 eligible patients with fever and neutropenia received piperacillin-tazobactam monotherapy. On day 3, according to the study protocol, 165 patients with persistent fever who fulfilled the study entry criteria were randomised to receive vancomycin or a placebo. The success rate was 51% in the intention-to-treat analysis and 62% in the per-protocol analysis. The overall mortality rate was 8% (58/763), with only 18 (2.4%) deaths attributed to the initial or subsequent infection. Randomisation had no influence on the study endpoints. The adverse event rate was evaluated only in the patient population not included in the randomised part of the study. Among these patients, adverse events probably or definitely related to piperacillin-tazobactam therapy were uncommon, confirming the favourable safety profile of piperacillin-tazobactam. It was concluded that piperacillin-tazobactam could be considered as monotherapy for patients with high-risk febrile neutropenia.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/therapeutic use, Child, Child, Preschool, Enzyme Inhibitors/administration & dosage, Enzyme Inhibitors/therapeutic use, Europe, Fever/drug therapy, Fever/etiology, Hematologic Neoplasms/complications, Humans, Infant, Injections, Intravenous, Middle Aged, Middle East, Neutropenia/drug therapy, Neutropenia/etiology, North America, Penicillanic Acid/administration & dosage, Penicillanic Acid/analogs & derivatives, Piperacillin/administration & dosage, Piperacillin/therapeutic use, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 13:31
Dernière modification de la notice
20/08/2019 15:43
Données d'usage